Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) Short Interest Update

Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) was the recipient of a significant drop in short interest in the month of July. As of July 31st, there was short interest totaling 16,560 shares, a drop of 89.2% from the July 15th total of 152,860 shares. Based on an average daily volume of 2 shares, the short-interest ratio is presently 8,280.0 days.

Neuren Pharmaceuticals Stock Performance

NURPF remained flat at C$17.00 during trading on Thursday. The company’s stock had a trading volume of 1,375 shares, compared to its average volume of 1,104. The firm has a 50-day moving average of C$11.98 and a two-hundred day moving average of C$10.13. Neuren Pharmaceuticals has a 12 month low of C$7.70 and a 12 month high of C$17.25.

About Neuren Pharmaceuticals

Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.

The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.